Ipilimumab vs Upadacitinib
Ipilimumab vs Upadacitinib: Overview
This comparison examines the pharmacological differences between Ipilimumab and Upadacitinib.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Upadacitinib — 9-14 hours.
Chemical Properties
Molecular Formula: Upadacitinib — C17H19F3N6O.
Molecular Weight: Upadacitinib — 380.3700 g/mol.
Type: Ipilimumab — Antibody; Upadacitinib — Small molecule.